Portfolio update: I’m currently down ~28% on Novo Nordisk this year.

 But I’m not waving a white flag — because sometimes a drop reveals opportunity, not failure.

šŸ“Œ The question: “Is this slump meaningful, or has the market over-corrected?”

Based on the latest numbers, my view is that Novo Nordisk is fairly valued to slightly undervalued — meaning I’m comfortable holding and believe there’s potential upside, but this isn’t a free-lunch scenario.

Staying focused, tracking the story, and playing the long game. #Investing #HealthCare #ValueMindset

Valuation Snapshot & Commentary

Here are the key points on Novo Nordisk’s valuation and risks:

Positive signals (supporting undervaluation/hold):

  • Trailing P/E is around ~14.3× and the forward P/E ~14.3-15× in many estimates. StockAnalysis+2StockAnalysis+2

  • The company has a strong market position in diabetes and obesity treatments (e.g., drugs like Ozempic and Wegovy) and global scale. Morningstar+1

Caution/overhangs (why it might not be cheap):

  • Novo Nordisk recently cut its full-year 2025 sales and operating profit growth forecasts due to competitive pressures and slower growth in key markets. Reuters+1

  • High reliance on a few blockbuster drugs means execution risk is elevated (competition, regulatory, pricing).

  • Lower multiples help, but they reflect increased uncertainty, which means margin for error is smaller.

My Verdict: Fair to Slightly Undervalued

Given the balance of factors:

  • The valuation metrics (P/E) suggest the market isn’t giving Novo Nordisk a wild premium — which is good if you believe in their long-term business.

  • The downside risk seems somewhat reflected in the share-price drop (so some bad news is baked in).

  • But because there are meaningful risks (competition, growth slowdown), I’d not call it a deep bargain.

  • So for me: fair value to slight undervaluation, with the expectation of moderate upside if things go right, rather than a high-flyer scenario.

If I were you, I’d stay invested (assuming you believe in the thesis) but keep a close eye on upcoming earnings, margin trends, and competitive dynamics.

Comments

Post a Comment

Popular posts from this blog

Update: Should I Buy, Sell, or Hold Travelzoo Stock Now I'm 8.5% Up?

  TZOO Travelzoo (NASDAQ: TZOO) has been a star performer in the travel and leisure sector, with its stock price surging +140.92% over the past year. As someone who is already 8.5% up since buying into the stock, I’ve been carefully weighing whether to hold, take profits, or even add to my position. Here’s my perspective based on the key metrics, forecasts, and broader trends. The Case for Holding (or Adding to) TZOO Strong Fundamentals Travelzoo has delivered impressive numbers, with $84.37 million in revenue and a 16.67% profit margin over the last 12 months. Its earnings per share (EPS) of $1.06, combined with a forward EPS growth forecast of 36.45%, signals continued financial strength. For someone like me, already enjoying an 8.5% gain, there’s room for even more upside. Positive Analyst Sentiment Analysts have set a 12-month price target of $25.00, a 22.37% increase from the current price of $20.43. The consensus rating of “Strong Buy” suggests that the market sees further up...
Read more

Portfolio update: I’m currently up ~30% on Blue Bird Corporation this year.

 Holding a business that’s executing rather than cheering short-term hype. šŸ“Œ But: “Is it still undervalued, or has the market already run ahead?” Based on current metrics and growth trajectory, my view is that Blue Bird is slightly undervalued — meaning I’m comfortable holding, believe there’s still upside — but I’m also realistic that some of the upside has already been baked in. Patience + seeing the bus roll (literally) = the combo. #Investing #ValueMindset #IndustrialGrowth Valuation Snapshot & Commentary Blue Bird’s current P/E is ~15-16× according to Simply Wall St. Simply Wall St +2 Simply Wall St +2 That P/E is below its peers in the machinery/industrial sector (peer avg ~17-18×) and below the industry average (~24×) per one analysis. Simply Wall St Intrinsic / DCF valuation models: One gives a fair value around US$66.82 vs current ~$55-60, suggesting ~20% upside. Value Investing +1 Company fundamentals: Strong recent results — in 2024 revenue gre...
Read more

Kaspi.kz Stock Analysis: A Deep Dive into Kazakhstan's Fintech Powerhouse

Kaspi.kz (NASDAQ: KSPI) has emerged as a standout player in the global fintech market, leveraging its dominance in Kazakhstan to create a robust ecosystem of financial services, payments, and e-commerce.  With an attractive valuation, strong fundamentals, and growth potential, this company offers investors a compelling story.  Background on Kaspi.kz Founded in Kazakhstan, Kaspi.kz has redefined the way financial services and e-commerce intersect in Central Asia. The company operates a "super app," integrating three pillars: Marketplace: E-commerce services connecting merchants and consumers. Payments: A digital wallet and payment solution for individuals and businesses. Financial Services: Consumer and business lending integrated with digital banking. Kaspi.kz’s business model thrives on its ability to bundle services, increasing customer stickiness while driving profitability. Its presence as a market leader in Kazakhstan—with limited competition—has allowed the company t...
Read more